Current Status of the Development Programs of New Indications and Formulations of Aricept® for Enhancing Patient Value
[ 2009/07/02 | Eisai Co., Ltd. | Pharmaceuticals | Tokyo | TSE1(PRIME) ]

The Company's Official Page
http://www.eisai.co.jp/enews/enews200924.html
Back To Previous Page
Dear User,
JPubb program could not collect the texts of this press-release from the official page, which perhaps mainly comprises tables, charts or images. Please refer to the official page indicated above. -- by JPubb

Latest News: Pharmaceuticals

    この内容でのリリース掲載はまだ無いか、集計されておりません。

more
    この内容でのリリース掲載はまだ無いか、集計されておりません。

more

Most Popular: Pharmaceuticals

1. Announcement on Foundation of Actavis AS...
ASKA Pharmaceutical Co., Ltd. 2009/04/01
2. Kaken licenses out Fiblast® Spray in...
Kaken Pharmaceutical Co.,Ltd. 2005/12/20
3. Current Status of the Development Progra...
Eisai Co., Ltd. 2009/07/02
4. Ajinomoto and Eisai Sign Agreement for D...
Eisai Co., Ltd. 2009/02/10
5. EISAI PROVIDES PRELIMINARY EFFICACY UPDA...
Eisai Co., Ltd. 2008/07/01

Latest News: Eisai Co., Ltd.


more

Most Popular: Eisai Co., Ltd.

1. EISAI PROVIDES PRELIMINARY EFFICACY UPDA...
2008/07/01
2. Brain Factory and Eisai Conclude License...
2010/09/30

Categories

Go to Page Top

View: Smartphone | PC

Language: English | Japanese

■Home

■Terms & Conditions

■Twitter ■Facebook

■About Us